In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Brainsway nets $25.6mm through IPO of ADSs on Nasdaq
01 May 2019
In its second attempt to list on Nasdaq, Brainsway Ltd. (deep transcranial magnetic stimulation device (TMS) for psychiatric, neurological, and addiction disorders) netted $25.6mm through its initial public offering of 2.5mm American Depositary Shares (ADSs, with each representing two ordinary shares) at $11 (or $5.50/share). Earlier this month the company announced it planned to sell 2.5mm ADSs at $11.94 apiece, or $5.97/share.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?